NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Bempedoic Acid Therapy for Patients with Statin Intolerance
Despite decades of progress in lipid lowering therapy, adequate LDL-C reduction remains a laudable but difficult to achieve goal, especially in patients with known ASCVD,…
Clinician Strategies for Facilitating Lifestyle Changes During COVID-19 and Beyond
Despite substantial improvements in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of death worldwide.
Case Study: Role of Sodium-Glucose Cotransporter 2 Inhibitors in Managing Residual Cardiovascular Risk
The following case involves a 58-yearold gentleman with a history of complex cardiovascular disease and several cardiometabolic risk factors as listed herein.
Telemedicine and the Patient Experience
Telemedicine is Here to Stay. Telemedicine is a valuable tool for patient care, but one that has been underused and underdeveloped for many years.
The Use of Colchicine for Secondary Cardiovascular Disease Prevention: What’s Old is New Again
Colchicine is an oral anti-inflammatory medication that interferes with neutrophil function and activation of IL-1β. The United States Food and Drug Administration-approved indications for colchicine…
Machine Learning to Detect Cardiovascular Complications of COVID-19
Since its emergence, the highly virulent coronavirus disease 2019 (COVID-19) has infected over 50 million people worldwide, and its cardiovascular (CV) manifestations have become an…
Non-Lipid Lowering Therapies Impacting Cardiovascular Disease Risk
Atherosclerosis is the leading cause of death and disability globally, with the highest burden continuing to have dominant impact in the developing world. Lipids play…
S2E3: Evinacumab: A new therapeutic option to treat dyslipidemia
Join Dr. Alan Brown and Dr. Robert Rosenson as they discuss evinacumab, a new therapeutic option for treating dyslipidemia.
